USPTO Art Unit 1614 Prosecution Statistics

Art Unit Information

Art Unit: 1614
Group: 1610
Tech Center: 1600
Total Cases: 8,406
Last Active: May 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19220988DISPENSER AND METHOD OF USE THEREOFMay 2025October 2025Allow410NoNo
19214778METHOD OF TREATING CANCER USING A ZrO2@CaSiO3@g-C3N4 NANOCOMPOSITE MATERIALMay 2025July 2025Allow200NoNo
19210389Herbicidal compositions comprising clethodimMay 2025December 2025Allow710NoNo
19204235RADIOPHARMACEUTICAL COMPOSITIONS FOR LOW TOXICITY ACTINIUM IN TARGETED RADIONUCLIDE THERAPYMay 2025August 2025Allow301NoNo
192025013-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the SameMay 2025September 2025Allow410NoNo
19193039Herbicidal compositions comprising isoxaflutoleApril 2025January 2026Allow810NoNo
19174523ANTICANCER AGENTS COMPRISING A g-C3N4@CuO/MgAl2O4 NANOHYBRIDApril 2025July 2025Allow310NoNo
19170693Herbicidal compositions comprising topramezoneApril 2025December 2025Allow810YesNo
19058112USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMORMarch 2025January 2026Abandon1101NoNo
19077428TRADITIONAL CHINESE HERBAL PLANT COMPOSITION FOR IMPROVING SYMPTOMS OF LIVER CANCER PATIENTS AND COMPATIBILITY METHOD THEREOFMarch 2025June 2025Allow300NoNo
19075007METHODS OF TREATING MIGRAINES WITH A COMBINATION OF A MELOXICAM AND A RIZATRIPTANMarch 2025November 2025Allow811YesNo
19064093INHIBITION OF CANCER CELL VIABILITYFebruary 2025April 2025Allow210NoNo
19064478Herbicidal compositions comprising mesotrioneFebruary 2025October 2025Allow710YesNo
19059879SILVER COMPOUND PREPARATION AND APPLICATION OF SILVER COMPOUND PREPARATION IN TREATMENT OF CUTANEOUS FUNGAL INFECTIONS AND ECZEMAFebruary 2025September 2025Allow710NoNo
19058927MULTI-ACTIVE INGREDIENT HERBICIDE COMPOSITIONS AND METHODSFebruary 2025August 2025Allow610YesNo
19056358CHEMICAL STRUCTURES THAT CONTROL METABOLIC ELIMINATION OF AMINOSTEROLSFebruary 2025October 2025Allow811YesNo
19051044PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYFebruary 2025September 2025Allow710NoNo
19002866THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITISDecember 2024September 2025Allow820NoNo
19000004SOLID PHASE COMPOSITIONS AND MANUFACTURING METHODS FOR ECTOPARASITICIDAL CONTROLDecember 2024September 2025Allow910YesNo
18985109COMPLEX MICROBIAL AGENT AND APPLICATIONS THEREOFDecember 2024July 2025Allow710YesNo
18979962LISINOPRIL FORMULATIONSDecember 2024July 2025Allow720NoNo
18976761COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOFDecember 2024April 2025Allow410YesNo
18975647Herbicidal compositions comprising 2,4-DDecember 2024June 2025Allow610YesNo
18952635COATED ZEOLITIC IMIDAZOLATE FRAMEWORK (ZIF-8) AS AN EFFICIENT CARRIER FOR THE CYCLOHEPTYLAMINE HYDROCHLORIDE FOR THE TREATMENT OF DIABETESNovember 2024September 2025Allow1020NoNo
18948050CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2024March 2025Allow410NoNo
18932263Herbicidal Compositions Comprising GlyphosateOctober 2024February 2026Allow1620NoNo
18928649OPIOID FORMULATIONSOctober 2024March 2025Allow410NoNo
18923620ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOFOctober 2024January 2025Allow310NoNo
18911031STORAGE STABLE GLUFOSINATE FORMULATIONOctober 2024March 2026Allow1720NoNo
18900318METHODS FOR THE CONTROL OF POA ANNUA IN WARM SEASON TURFGRASS USING THIENCARBAZONE-METHYLSeptember 2024August 2025Allow1020YesNo
18823257PHARMACEUTICAL COMPOSITIONSeptember 2024March 2025Allow610NoNo
18823274PHARMACEUTICAL COMPOSITIONSeptember 2024April 2025Allow710NoNo
18788060NANO-DELIVERY CARRIER FOR TARGETED TUMOR ADMINISTRATION AND APPLICATION THEREOFJuly 2024November 2024Allow300NoNo
18754225BACILLUS VELEZENSIS STRAIN FOR PREVENTING AND CONTROLLING EARLY BOLTING OF ANGELICA SINENSIS, MICROBIAL AGENT AND USE THEREOFJune 2024August 2025Allow1410NoNo
18739646Safe Flavoring Composition to Improve Compliance in Colon Cleansing CompositionsJune 2024March 2025Abandon910NoNo
18732203COMPOSITIONS FOR TREATMENT OF DISCOGENIC PAIN, AND PROCESSES FOR MAKING AND USING THE SAMEJune 2024December 2024Allow710YesNo
18672876TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEMay 2024September 2024Allow300NoNo
18668526METHOD TO SELECTIVELY PRODUCE BENZALANILINE FROM A SCHIFF-BASE REACTION INVOLVING ANILINE AND BENZALDEHYDEMay 2024February 2025Allow920NoNo
18669214LIPIDS AND LIPID NANOPARTICLE FORMULATIONSMay 2024October 2024Allow501NoNo
18665612IMMUNOMODULATING TREATMENTS OF BODY CAVITIESMay 2024December 2024Allow810YesNo
18663349LISINOPRIL FORMULATIONSMay 2024October 2024Allow510YesNo
18659997COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEAMay 2024November 2025Abandon1801NoNo
18653608TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEMay 2024October 2024Allow510NoNo
18648426TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIBApril 2024March 2025Allow1020NoNo
18647511METHODS AND COMPOSITIONS FOR TREATING CANCERApril 2024April 2025Allow1220YesNo
18639758KAVA COMPOSITIONS AND METHODS OF USEApril 2024May 2025Abandon1320NoNo
18637083INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTSApril 2024April 2025Allow1210NoNo
18632908PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUSApril 2024December 2025Allow2021NoNo
18630283METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERSApril 2024November 2025Abandon1910NoNo
18624670TREATMENTS WITH NIROGACESTATApril 2024October 2024Allow620NoNo
18621397METHODS AND COMPOSITIONS FOR MANAGING PAIN COMPRISING DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONSMarch 2024February 2026Abandon2230NoNo
18621669Local Drug Delivery Devices and Methods for Treating CancerMarch 2024December 2025Allow2010NoNo
18618110SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORSMarch 2024February 2025Allow1121NoNo
18617058LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONSMarch 2024December 2025Allow2111NoNo
18609128DRIED NANOPARTICLE COMPOSITIONSMarch 2024October 2024Allow710NoNo
18600574COMPOSITIONS AND METHODS FOR HAIR TREATMENTMarch 2024August 2025Allow1741NoNo
18594898MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONEMarch 2024July 2025Allow1620NoNo
18587211SURFACE GRADIENT CROSS-LINKING METHOD OF ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE AND THE APPLICATION THEREOFFebruary 2024February 2026Allow2420NoNo
18587175ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOFFebruary 2024January 2025Allow1111NoNo
18583696METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSFebruary 2024January 2025Abandon1110NoNo
18581735COSMETIC SKINCARE COMPOSITION COMPRISING PROBIOTIC MICROORGANISMS AND PREBIOTIC COMPOUNDSFebruary 2024November 2025Abandon2110NoNo
18581307SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USEFebruary 2024April 2025Allow1411NoNo
18443875HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2024December 2024Abandon1001NoNo
18441413MAGNESIUM BIOTINATE COMPOSITIONS AND METHODS OF USEFebruary 2024February 2025Allow1201NoNo
18439677FABRICATION OF NOVEL NANO-SIZED [4{3,4-BIS-[(5-BROMO-2-HYDROXY-BENZYLIDENE)-AMINO]-PHENYL}-PHENYL-METHANONE] RU(III) COMPLEX FOR PHARMACEUTICAL APPLICATIONSFebruary 2024August 2024Allow610NoNo
18574378CRYSTAL FORM OF TRIAZOLOPYRIDINE-SUBSTITUTED INDAZOLE COMPOUND AND PREPARATION METHOD THEREFORFebruary 2024March 2026Allow2600NoNo
18417750COMPOSITIONS COMPRISING AN UROLITHIN COMPOUNDJanuary 2024January 2025Allow1210NoNo
18414185TREATMENTS WITH NIROGACESTATJanuary 2024August 2024Allow710NoNo
18411219TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORMJanuary 2024February 2026Abandon2501NoNo
18405670EYE DROP COMPOSITIONJanuary 2024November 2024Allow1010NoNo
18403636TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICEJanuary 2024August 2025Abandon1910NoNo
18399875FOAM TREATMENT METHOD FOR BACTERIADecember 2023January 2026Allow2520NoNo
18543199SOLID SUBSTRATES FOR PROMOTING CELL AND TISSUE GROWTHDecember 2023June 2025Allow1810NoNo
18541291SUPRAMOLECULAR BIOMEDICAL POLYMERSDecember 2023December 2025Allow2420YesNo
18570072ULTRASOUND-RESPONSIVE LIPOSOME NANOPARTICLES AND PREPARATION METHOD AND USE THEREOFDecember 2023December 2025Allow2410NoNo
18539781BRANCHED-CHAIN AMINO ACID DERIVATIVES TO TREAT DISEASEDecember 2023March 2026Allow2700YesNo
18538562METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVESDecember 2023March 2025Abandon1510NoNo
18567972Treatment for Down Syndrome-Related Accelerated AgingDecember 2023March 2026Allow2710NoNo
18533062WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLESDecember 2023May 2025Abandon1830YesNo
18524148HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENTNovember 2023April 2025Abandon1610NoNo
18565865MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERSNovember 2023February 2026Allow2610NoNo
18517529PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYNovember 2023October 2024Allow1110NoNo
18516052Solid Drug Tablets for Implantable Drug Delivery DevicesNovember 2023June 2025Allow1810YesNo
18511294SYNTHETIC ENAMEL AND USES THEREOFNovember 2023March 2025Allow1630NoNo
18511152METHOD OF MAKING SILVER NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAMENovember 2023December 2024Allow1320NoNo
18389181ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTSNovember 2023November 2024Abandon1220NoNo
18289738A PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOFNovember 2023September 2025Allow2300NoNo
18501774QUATERNARY DISINFECTANT COMPOSITION WITH ANIONIC SCALE INHIBITING AGENTNovember 2023December 2025Allow2630NoNo
18386906CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2023March 2025Allow1620NoNo
18500595OPIOID FORMULATIONSNovember 2023July 2024Allow912NoNo
18500603OPIOID FORMULATIONSNovember 2023June 2025Abandon1920YesYes
18289215MAPPING NANOPARTICLESNovember 2023December 2025Allow2640NoNo
18498542ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCEROctober 2023January 2025Allow1520NoNo
18496417Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive BlockingOctober 2023July 2024Allow810NoNo
18493090QUATERNARY AMMONIUM CYCLODEXTRIN AND PREPARATION METHOD AND USES THEREOF, AND SILVER NANOPARTICLE-CYCLODEXTRIN COMPLEX AND PREPARATION METHOD AND USES THEREOFOctober 2023December 2024Allow1421NoNo
18556634PURIFIED PSYCHOACTIVE ALKALOID EXTRACTION USING ACIDIFIED ACETONEOctober 2023May 2025Abandon1811NoNo
18381775COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGSOctober 2023February 2025Abandon1631YesNo
18381351DISPENSER AND METHOD OF USE THEREOFOctober 2023October 2024Allow1100NoNo
18287446IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPYOctober 2023March 2026Allow2920NoNo
18286675Radiopharmaceuticals at Different Activity Reference TimesOctober 2023August 2025Allow2221NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1614.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
105
Examiner Affirmed
69
(65.7%)
Examiner Reversed
36
(34.3%)
Reversal Percentile
59.5%
Higher than average

What This Means

With a 34.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
870
Allowed After Appeal Filing
193
(22.2%)
Not Allowed After Appeal Filing
677
(77.8%)
Filing Benefit Percentile
9.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1614 - Prosecution Statistics Summary

Executive Summary

Art Unit 1614 is part of Group 1610 in Technology Center 1600. This art unit has examined 8,406 patent applications in our dataset, with an overall allowance rate of 46.7%. Applications typically reach final disposition in approximately 30 months.

Comparative Analysis

Art Unit 1614's allowance rate of 46.7% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1614 receive an average of 1.82 office actions before reaching final disposition (in the 44% percentile). The median prosecution time is 30 months (in the 53% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.